Perampanel – trademarked Fycompa – is a relatively new epilepsy drug manufactured by Eisai. On 8 July, the drug was made available in the UK through the NHS.
Fycompa is a first-in-class anti-epileptic drug (AED). This means that it is the first drug to affect the brain in this specific way. The drug dampens epileptic activity in a particular type of receptor in the brain.
Because it works differently than the drugs that have gone before it, it is hoped that Fycompa will control seizures in people where other treatments have failed.
Fycompa is now available through the NHS for the treatment of primary generalised tonic-clonic (PGTC) seizures in cases of idiopathic generalised epilepsy (IGE).
Fycompa is the first new treatment designed to combat PGTC seizures in five years. In clinical trials, 31 per cent of people (almost a third) achieved seizure freedom when Fycompa was added to their treatment regime.
Prof Ley Sander is a consultant neurologist at the National Hospital and at the Chalfont Centre for Epilepsy. Prof Sander said: “The launch of perampanel in the UK for refractory generalised convulsions is welcome news for people living with this type of seizure.
“Perampanel has a novel mechanism of action and this may explain why some people have such an excellent response in terms of seizure response from these convulsions. Indeed, seizure freedom allows many of these people to lead a more normal life.”
You may also like...
International pharmaceutical company Eisai today held a press conference on their new epilepsy medicine, Fycompa. Will this genuinely show an improvement in treatment for people living with the condition?